SYRS (SYRS) Stock Price & Analysis
SYRS (SYRS) rose 0.00% to USD 0 as of July 25, 2026 at 03:03 UTC, according to Nexqual real-time market data.
SYRS last closed at USD 0; the session ranged USD 0–0 on volume of 904 shares. Market capitalization is $2,683, with a 52-week range of USD 0–0.03 (PNK). Source: Nexqual, July 25, 2026 at 03:03 UTC.
Key Statistics (as of July 25, 2026 at 03:03 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.03 |
| Volume | 904 shares |
| Market Cap | $2,683 |
| Exchange | PNK |
Technical Analysis (SYRS)
Nexqual's technical model rates SYRS "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 03:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.41 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (SYRS)
Wall Street analysts rate SYRS "None" based on 4 analysts, with a mean price target of USD 8.75 (range USD 4–20), per Nexqual as of July 25, 2026 at 03:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 8.75 |
| High Target | USD 20 |
| Low Target | USD 4 |
Earnings (SYRS)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-09-30 | USD -0.16 vs est -0.67 ▲ beat |
| 2024-06-30 | USD -0.59 vs est -0.77 ▲ beat |
| 2024-03-31 | USD -0.1 vs est -0.94 ▲ beat |
| 2023-12-31 | USD -2.22 vs est -1.12 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financials & Fundamentals (SYRS)
| Total Revenue | $386,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -28891.71% |
| Profit Margin | +0.00% |
| ROE | -776.96% |
| Current Ratio | 2.25 |
| Total Cash | $58.27M |
| Total Debt | $60.23M |
| Free Cash Flow | $-57.94M |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financial Health Score (SYRS)
Nexqual rates SYRS's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:03 UTC.
| Growth | Critical — Revenue -33% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $58M cash vs $60M debt |
| Cash Flow | Weak — FCF negative: -$58M, burning cash |
| Efficiency | Critical — ROE -777%, ROA -59.9% |
Ownership (SYRS)
| Insider Ownership | +0.07% |
|---|---|
| Institutional Ownership | +9.62% |
| Shares Outstanding | 26.83M |
| Float | 26.83M |
| Short % of Float | +3.81% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MCRB | Seres Therapeutics, Inc. | USD 4.97 | ▼ 5.97% |
| CGEN | Compugen Ltd. | USD 2.28 | ▼ 5.79% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| CALA | Calithera Biosciences, Inc. | USD 0 | ▲ 0% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:03 UTC. This page is informational and not investment advice.